LRC-CPPTLipid Research Clinics Study Coronary Primary Prevention Trial
References in periodicals archive ?
Two trials of the effects of cholestyramine therapy conducted in the 1970s, the LRC-CPPT study (26,61) and the National Heart, Lung, and Blood Institute (NHLBI) Type II Coronary Intervention Study, (27,62) demonstrated that BAS significantly lowered TC and LDL-C.
LRC-CPPT was a double-blind, placebo-controlled trial of the effects of cholestyramine on the prevention of CAD in 3,806 men with primary hypercholesterolemia.
LRC-CPPT, which compared cardiovascular outcomes in 3,806 men treated double-blind with BAS or placebo, was one of the first large studies to definitively associate a reduction in LDL-C with a reduction in CAD risk.